Liquid Biopsy Markets By Cancer, Usage, Biomarker, Place, & Product With Price And Volume Outlook. Including Executive and Consultant Guides and Customized Forecasting and Analysis 2023-2027

The Screening, Diagnostic, Therapy Selection, Minimal Residual Disease and Screening Market Potential are all explored in this report. We look at Price and Volume Outlooks by type of cancer. This report provides detailed analysis.

Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology has created the possibility of widespread cancer screening tests.

Illumina is now working on the Circulating Cell-Free Genome Atlas (CCGA) to help identify cancer early. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has just moved into a new growth phase. The impact on the health care industry is enormous. The report forecasts the market size looking out 5 years. In addition, the report looks at potential market sizes by country, by cancer and by the four types of usage: screening, diagnosis, therapy selection and recurrence monitoring.

The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate, Cervical, and Other Cancers as well as breakouts by Screening/Early Detection, Diagnostic, Therapy Monitoring and Recurrence Monitoring.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

B.Sc. (Chemistry) University of BC
M.B.A. (Finance and Policy) University of BC
Market Research Seminar - Burke Institute
Finance for Senior Executives - Harvard Business School

1. Market Guides

1.1. Liquid Biopsy Market-Strategic Situation Analysis
1.2. Guide for Executives, Marketing, Sales, and Business Development Staff
1.3. Guide for Management Consultants and Investment Advisors

2. Introduction and Market Definition

2.1. What is Liquid Biopsy?
2.2. The Sequencing Revolution
2.3. Market Definition
- 2.3.1. Revenue Market Size
2.4. Methodology
- 2.4.1. Methodology
- 2.4.2. Sources
- 2.4.3. Authors
2.5. Perspective: Healthcare and the IVD Industry
- 2.5.1. Global Healthcare Spending
- 2.5.2. Spending on Diagnostics
- 2.5.3. Important Role of Insurance for Diagnostics

3. Market Overview

3.1. Players in a Dynamic Market
- 3.1.1. Academic Research Lab
- 3.1.2. Diagnostic Test Developer
- 3.1.3. Instrumentation Supplier
- 3.1.4. Chemical/Reagent Supplier
- 3.1.5. Pathology Supplier
- 3.1.6. Independent Clinical Laboratory
- 3.1.7. Public National/regional Laboratory
- 3.1.8. Hospital Laboratory
- 3.1.9. Physicians Office Lab (POLS)
- 3.1.10. Audit Body
- 3.1.11. Certification Body
3.2. Using Biopsies
- 3.2.1. Cancer
- 3.2.2. Precancerous conditions
- 3.2.3. Inflammatory conditions
3.3. Biopsy Sites
3.4. The Situation Today - Biopsy Analysis
3.5. Evidence of Cancer-Liquid Biopsy Technology
- 3.5.1. The Big Picture on Liquid Biopsy Technology
- 3.5.2. The Role of CTCs
- 3.5.3. Application of CTCs
- 3.5.4. CellSearch Detection- Ultimate Sensitivity
- 3.5.5. Epic Sciences Detection- Imaging Takes the Lead
- 3.5.6. Maintrac Detection - The Microscope
- 3.5.7. Other Methods
- 3.5.8. ctDNA Role
- 3.5.9. ctDNA Applications
- 3.5.10. Exosomes and Micro Vesicles - New Kid on the Block
- 3.5.11. The Multiple Play
3.6. Cancer Treatment Protocol Under Siege
- 3.6.1. Issues to Liquid Biopsy Adoption - Double Diagnostics
- 3.6.2. The Cancer Screening Market Opportunity
  - 3.6.2.1. GRAIL - What Is It?
- 3.6.3. Cancer Management vs. Diagnosis
  - 3.6.3.1. The Role of Risk Assessment
  - 3.6.3.2. Managing Therapy
  - 3.6.3.3. Monitoring Disease - What Is It?
- 3.6.4. Phases of Adoption - Looking into The Future
- 3.6.5. The Promise of Liquid Biopsy
3.7. Structure of Industry Plays a Part
- 3.7.1. Hospital Testing Share
- 3.7.2. Economies of Scale
  - 3.7.2.1. Hospital vs. Central Lab
- 3.7.3. Physician Office Lab's
- 3.7.4. Physician's and POCT

4. Market Trends

4.1. Factors Driving Growth
- 4.1.1. Non-Invasive Game Changer
- 4.1.2. Lower Cost
- 4.1.3. Greater Accuracy
- 4.1.4. Wide Range of Potential Uses
- 4.1.5. Aging Population
4.2. Factors Limiting Growth
- 4.2.1. Lower prices
- 4.2.2. Lack of Standards
- 4.2.3. Protocol Resistance
- 4.2.4. Initial Adoption Cost
- 4.2.5. Conclusion
4.3. Instrumentation and Automation
- 4.3.1. Instruments Key to Market Share
- 4.3.2. Bioinformatics Plays a Role
4.4. Diagnostic Technology Development
- 4.4.1. Next Generation Sequencing Fuels a Revolution
- 4.4.2. Impact of NGS on pricing
- 4.4.3. Pharmacogenomics Blurs Diagnosis and Treatment
- 4.4.4. CGES Testing, A Brave New World
- 4.4.5. Biochips/Giant magneto resistance based assay

5. Liquid Biopsy Recent Developments

5.1. Recent Developments - Importance and How to Use This Section
- 5.1.1. Importance of These Developments
- 5.1.2. How to Use This Section
5.2. Liquid Biopsy Shortens Time to Treatment
5.3. Guardant Health MRD Test Garners Coverage
5.4. IMBdx, AstraZeneca Expand Prostate Cancer Liquid Biopsy Partnership
5.5. FoundationOne Liquid Biopsy Assay Gets FDA OK as Companion Diagnostic
5.6. Epic Sciences Raises $24M for Breast Cancer Liquid Biopsy Test
5.7. GenoMe Diagnostics Preparing DPCR-Based Ovarian Cancer Test
5.8. Sophia Genetics to Commercialize Liquid Biopsy Test
5.9. Agilent, Qiagen Nab FDA Approvals for Lung Cancer Treatment CDx
5.10. Liquid Biopsy Startup Haystack Oncology Raises $56M
5.11. Hedera Dx to Launch Liquid Biopsy Streamlined Platform
5.12. PamGene Expanding Liquid Biopsy Assays
5.13. Liquid Biopsy Firm Hedera Dx Raises €14M
5.14. MDxHealth Plans One-Stop Shop for Prostate Cancer Dx
5.15. Precision Oncology Dx Access Varies Widely in Europe
5.16. Extracellular Vesicles Show Promise as Early-Stage Cancer Diagnostic
5.17. Predicine Receives CE Mark for Blood and Urine Liquid Biopsy
5.18. BillionToOne Launches First Liquid Biopsy Products
5.19. Dxcover Advances Multicancer Detection Platform
5.20. CorePath Laboratories, Cizzle Biotechnology Partner on Lung Cancer Blood Test
5.21. Illumina Sues Guardant Health Over Patents
5.22. Invitae to Expand Cancer Testing Portfolio
5.23. Cancer Centre, Inivata Partner on Clinical Liquid Biopsy Studies
5.24. IVBH Bio Takes Aim at With Liquid Biopsy Incubator
5.25. Molecular Health, Eone-Diagnomics Ink Liquid Biopsy Partnership
5.26. Delfi Diagnostics Looks To Fragmentation-Based Liquid Biopsy Tech
5.27. BillionToOne Adapting Fetal Dx Tech for Liquid Biopsy
5.28. EDGC to Expand Liquid Biopsy Space With Cell-Free DNA Platform
5.29. Liquid Biopsy Startup BioCaptiva Raises £1M in Seed Funding
5.30. Agilent Enters Liquid Biopsy Market with Resolution Biosciences Acquisition
5.31. Bio-Techne to Acquire Asuragen for up to $320M
5.32. Personalis Broadens Liquid Biopsy Offering
5.33. Exact Sciences to Offer End-to-End Cancer Testing With Ashion Acquisition
5.34. Delfi Diagnostics Plans Multi-Cancer Screening Test
5.35. Menarini's CellSearch Shows Potential to Predict Breast Cancer Prognosis, Treatment Response
5.36. Liquid Biopsy NGS Panels-Diverse Test Claims
5.37. CMS Colon Cancer Screening Memo Bodes Well for Assays
5.38. Natera Liquid Biopsy Test Coverage to Expand
5.39. Freenome Closes Financing to Support Early Cancer Detection Trial
5.40. C$2.6M Liquid Biopsy Initiative
5.41. NeoGenomics, Inivata Partner for Lung Cancer Liquid Biopsy
5.42. Liquid Biopsy Shows Promise as Screen for Cancers
5.43. Inivata launches RaDaR™ for the detection of residual disease and recurrence
5.44. Liquid Biopsy Assay Detects 50+ Types of Cancer
5.45. Liquid Biopsy Study Confirms Concordance with Tissue Biopsy

6. Profiles of Key Players

6.1. Abbott Laboratories
6.2. AccuraGen Inc.
6.3. Acuamark Diagnostics
6.4. Admera Health, LLC
6.5. Agilent/Dako
6.6. Amoy Diagnostics Co., Ltd.
6.7. Anchor Dx
6.8. ANGLE plc
6.9. Applied DNA Sciences
6.10. ARUP Laboratories
6.11. AVIVA Systems Biology
6.12. Baylor Miraca Genetics Laboratories
6.13. Beckman Coulter Diagnostics
6.14. Becton, Dickinson and Company
6.15. BGI Genomics Co. Ltd
6.16. Bioarray Genetics
6.17. Biocartis
6.18. Biocept, Inc.
6.19. Biodesix Inc.
6.20. BioFluidica
6.21. bioMérieux Diagnostics
6.22. Bioneer Corporation
6.23. Bio-Rad Laboratories, Inc
6.24. Bio-Techne
6.25. Bioview
6.26. Bolidics
6.27. Boreal Genomics
6.28. Burning Rock
6.29. Cardiff Oncology
6.30. Caris Molecular Diagnostics
6.31. CellCarta
6.32. CellMax Life
6.33. Cepheid (Danaher)
6.34. Circulogene
6.35. Cizzle Biotech
6.36. Clinical Genomics
6.37. Cytolumina Technologies Corp.
6.38. Datar Cancer Genetics Limited
6.39. Diagnologix LLC
6.40. Dxcover
6.41. Enzo Biochem
6.42. Epic Sciences
6.43. Epigenomics AG
6.44. Eurofins Scientific
6.45. Exact Sciences
6.46. Fluxion Biosciences
6.47. Freenome
6.48. Fyr Diagnostics
6.49. GeneFirst Ltd.
6.50. Genetron Holdings
6.51. GILUPI Nanomedizin
6.52. Guardant Health
6.53. HansaBiomed
6.54. Haystack Oncology
6.55. HeiScreen
6.56. Helomics
6.57. iCellate
6.58. ICON PLC
6.59. Illumina
6.60. Incell Dx
6.61. Inivata
6.62. INOVIQ
6.63. Integrated Diagnostics
6.64. Invitae Corporation
6.65. Janssen Diagnostics
6.66. Lunglife AI Inc
6.67. MDNA Life SCIENCES, Inc.
6.68. MDx Health
6.69. Menarini Silicon Biosystems
6.70. Mesa Laboratories, Inc.
6.71. Millipore Sigma
6.72. Miltenyi Biotec
6.73. miR Scientific
6.74. Myriad Genetics/Myriad RBM
6.75. NantHealth, Inc.
6.76. Natera
6.77. NeoGenomics
6.78. Novogene Bioinformatics Technology Co., Ltd.
6.79. On-Chip Biotechnologies
6.80. Oncocyte
6.81. OncoDNA
6.82. Oxford Nanopore Technologies
6.83. PamGene
6.84. Panagene
6.85. Perkin Elmer
6.86. Personal Genome Diagnostics
6.87. Precision Medicine Group
6.88. PrecisionMed
6.89. Predicine
6.90. Promega
6.91. Qiagen
6.92. Rarecells SAS
6.93. RareCyte
6.94. Roche Molecular Diagnostics
6.95. Screencell
6.96. Siemens Healthineers
6.97. simfo GmbH
6.98. Singlera Genomics Inc.
6.99. Standard BioTools
6.100. Sysmex Inostics
6.101. Tempus Labs, Inc.
6.102. Thermo Fisher Scientific Inc.
6.103. Todos Medical
6.104. Veracyte
6.105. Volition
6.106. Vortex Biosciences

7. The Global Market for Liquid Biopsy Diagnostics

7.1. Global Market Overview by Country
- 7.1.1. Table - Global Market by Country
- 7.1.2. Chart-Global Market by Country
7.2. Global Market by Cancer-Overview
- 7.2.1. Table - Global Market by Cancer
- 7.2.2. Chart - Global Market by Cancer - Base/Final Year Comparison
- 7.2.3. Chart - Global Market by Cancer - Base Year
- 7.2.4. Chart - Global Market by Cancer - End Year
- 7.2.5. Chart - Global Market by Cancer - Share by Year
- 7.2.6. Chart - Global Market by Cancer - Segments Growth
7.3. Global Market by Usage-Overview
- 7.3.1. Table - Global Market by Usage
- 7.3.2. Chart - Global Market by Usage - Base/Final Year Comparison
- 7.3.3. Chart - Global Market by Usage - Base Year
- 7.3.4. Chart - Global Market by Usage - End Year
- 7.3.5. Chart - Global Market by Usage - Share by Year
- 7.3.6. Chart - Global Market by Usage - Segments Growth
7.4. Global Market by Place-Overview
- 7.4.1. Table - Global Market by Place
- 7.4.2. Chart - Global Market by Place - Base/Final Year Comparison
- 7.4.3. Chart - Global Market by Place - Base Year
- 7.4.4. Chart - Global Market by Place - End Year
- 7.4.5. Chart - Global Market by Place - Share by Year
- 7.4.6. Chart - Global Market by Place - Segments Growth
7.5. Global Market by Marker-Overview
- 7.5.1. Table - Global Market by Marker
- 7.5.2. Chart - Global Market by Marker - Base/Final Year Comparison
- 7.5.3. Chart - Global Market by Marker - Base Year
- 7.5.4. Chart - Global Market by Marker - End Year
- 7.5.5. Chart - Global Market by Marker - Share by Year
- 7.5.6. Chart - Global Market by Marker - Segments Growth
7.6. Global Market by Product-Overview
- 7.6.1. Table - Global Market by Product
- 7.6.2. Chart - Global Market by Product - Base/Final Year Comparison
- 7.6.3. Chart - Global Market by Product - Base Year
- 7.6.4. Chart - Global Market by Product - End Year
- 7.6.5. Chart - Global Market by Product - Share by Year
- 7.6.6. Chart - Global Market by Product - Segments Growth

8. Global Liquid Biopsy Diagnostic Markets - By Cancer

8.1. Breast
- 8.1.1. Table Breast - by Country
- 8.1.2. Table Breast - by Country, Price
- 8.1.3. Table Breast - by Country Volume
- 8.1.4. Chart-Breast Growth
8.2. Colorectal
- 8.2.1. Table Colorectal - by Country
- 8.2.2. Table Colorectal - by Country, Price
- 8.2.3. Table Colorectal - by Country, Volume
- 8.2.4. Chart-Colorectal Growth
8.3. Cervical
- 8.3.1. Table Cervical - by Country
- 8.3.2. Table Cervical - by Country, Price
- 8.3.3. Table Cervical - by Country, Volume
- 8.3.4. Chart-Cervical Growth
8.4. Lung
- 8.4.1. Table Lung - by Country
- 8.4.2. Table Lung - by Country, Price
- 8.4.3. Table Lung - by Country, Volume
- 8.4.4. Chart-Lung Growth
8.5. Prostate
- 8.5.1. Table Prostate - by Country
- 8.5.2. Table Prostate - by Country, Price
- 8.5.3. Table Prostate - by Country, Volume
- 8.5.4. Chart - Prostate Growth
8.6. Other
- 8.6.1. Table Other - by Country
- 8.6.2. Table Other - by Country, Price
- 8.6.3. Table Other - by Country, Volume
- 8.6.4. Chart-Other Growth

9. Global Liquid Biopsy Diagnostic Markets - by Usage

9.1. Screening
- 9.1.1. Table Screening - by Country
9.2. Chart-Screening Growth
9.3. Diagnostic
- 9.3.1. Table Diagnostic - by Country
- 9.3.2. Chart-Diagnostic Growth
9.4. Therapy
- 9.4.1. Table Therapy - by Country
- 9.4.2. Chart-Therapy Growth
9.5. Monitor
- 9.5.1. Table Monitor - by Country
- 9.5.2. Chart-Monitor Growth

10. Global Liquid Biopsy Diagnostic Markets - by Place

10.1. Hospital Lab
- 10.1.1. Table Hospital Lab - by Country
- 10.1.2. Chart-Hospital Lab Growth
10.2. Lab Service
- 10.2.1. Table Lab Service - by Country
- 10.2.2. Chart-Lab Service Growth
10.3. Lab Outpatient
- 10.3.1. Table Lab Outpatient - by Country
- 10.3.2. Chart-Lab Outpatient Growth
10.4. Other Lab
- 10.4.1. Table Other Lab - by Country
- 10.4.2. Chart-Other Lab Growth

11. Global Liquid Biopsy Diagnostic Markets - by Marker

11.1. Circulating Tumor Cell
- 11.1.1. Table Circulating Tumor Cell - by Country
- 11.1.2. Chart-Circulating Tumor Cell Growth
11.2. Cell Free DNA
- 11.2.1. Table Cell Free DNA - by Country
- 11.2.2. Chart-Cell Free DNA Growth
11.3. Vesicle
- 11.3.1. Table Vesicle - by Country
- 11.3.2. Chart-Vesicle Growth
11.4. Other Marker
- 11.4.1. Table Other Marker - by Country
- 11.4.2. Chart-Other Marker Growth

12. Global Liquid Biopsy Diagnostic Markets - by Product

12.1. Kits
- 12.1.1. Table Kits - by Country
- 12.1.2. Chart-Kits Growth
12.2. Instruments
- 12.2.1. Table Instruments - by Country
- 12.2.2. Chart-Instruments Growth
12.3. Service
- 12.3.1. Table Service - by Country
- 12.3.2. Chart-Service Growth

13. Appendices

13.1. United States Medicare System: Clinical Laboratory Fees Schedule

Table of Tables

Table 1: Market Players by Type
Table 2: Biopsy Sites
Table 3: LB Clinical Applications by Entity
Table 4: Advantages of Liquid Biopsy in Screening Market
Table 5: Outlook-Phases of Liquid Biopsy Adoption by Year
Table 6: Five Factors Driving Growth
Table 7: Factors Limiting Growth
Table 8: Key Diagnostic Laboratory Technology Trends
Table 9: Next Generation Sequencing Technologies - Speed and Cost
Table 10: Global Market by Region
Table 11: Global Market by Cancer
Table 12: Global Market by Usage
Table 13: Global Market by Place
Table 14: Global Market by Marker
Table 15: Global Market by Product
Table 16: Breast by Country
Table 17: Breast by Country Price
Table 18: Breast by Country Volume
Table 19: Colorectal by Country
Table 20: Colorectal by Country Price
Table 21: Colorectal by Country Volume
Table 22: Cervical by Country
Table 23: Cervical by Country Price
Table 24: Cervical by Country Volume
Table 25: Lung by Country
Table 26: Lung by Country Price
Table 27: Lung by Country Volume
Table 28: Prostate by Country
Table 29: Prostate by Country Price
Table 30: Prostate by Country Volume
Table 31: Other by Country
Table 32: Other by Country Price
Table 33: Other by Country Volume
Table 34: Screening by Country
Table 35: Diagnostic by Country
Table 36: Therapy by Country
Table 37: Monitor by Country
Table 38: Hospital Lab by Country
Table 39: Lab Service by Country
Table 40: Lab Outpatient by Country
Table 41: Other Lab by Country
Table 42: Circulating Tumor Cell by Country
Table 43: Cell Free DNA by Country
Table 44: Vesicle by Country
Table 45: Other Marker by Country
Table 46: Kits by Country
Table 47: Instruments by Country
Table 48: Service by Country
Table 49: Clinical Lab Fee Schedule

Table of Figures

Figure 1: Global Healthcare Spending Picture
Figure 2: The Global Lab Test Pie
Figure 3: The Road to Diagnostics
Figure 4: Comparison of Liquid vs Tissue Biopsy
Figure 5: Entities Analyzed in liquid Biopsy
Figure 6: Characteristics of Different Vesicle Types
Figure 7: The Changing Age of World Population
Figure 8: Health Care Consumption by Age
Figure 9: Cancer Incidence-Age at Diagnosis
Figure 10: Global Market Regional Share Chart
Figure 11: Global Market by Cancer-Base vs. Final
Figure 12: Global Market by Cancer Base Year
Figure 13: Global Market by Cancer End Year
Figure 14: Cancer Share by Year
Figure 15: Cancer Segments Growth
Figure 16: Global Market by Usage-Base vs. Final
Figure 17: Global Market by Usage Base Year
Figure 18: Global Market by Usage End Year
Figure 19: Usage Share by Year
Figure 20: Usage Segments Growth
Figure 21: Global Market by Place-Base vs. Final
Figure 22: Global Market by Place Base Year
Figure 23: Global Market by Place End Year
Figure 24: Place Share by Year
Figure 25: Place Segments Growth
Figure 26: Global Market by Marker-Base vs. Final
Figure 27: Global Market by Marker Base Year
Figure 28: Global Market by Marker End Year
Figure 29: Marker Share by Year
Figure 30: Marker Segments Growth
Figure 31: Global Market by Product-Base vs. Final
Figure 32: Global Market by Product Base Year
Figure 33: Global Market by Product End Year
Figure 34: Product Share by Year
Figure 35: Product Segments Growth
Figure 36: Breast Growth
Figure 37: Colorectal Diagnostics Growth
Figure 38: Cervical Growth
Figure 39: Lung Growth
Figure 40: Prostate Growth
Figure 41: Other Growth
Figure 42: Screening Growth
Figure 43: Diagnostic Growth
Figure 44: Therapy Growth
Figure 45: Monitor Growth
Figure 46: Hospital Lab Growth
Figure 47: Lab Service Growth
Figure 48: Lab Outpatient Growth
Figure 49: Other Lab Growth
Figure 50: Circulating Tumor Cell Growth
Figure 51: Cell Free DNA Growth
Figure 52: Vesicle Growth
Figure 53: Other Marker Growth
Figure 54: Kits Growth
Figure 55: Instruments Growth
Figure 56: Service Growth